杜托 Joaquin Duato — 强生 CEO
FORTUNE 500 #131

杜托

Joaquin Duato

强生 (Johnson & Johnson)

领导U.S.大型Pharmaceuticals企业运营

广告

专业领域

医疗健康管理 生命科学

Healthcare management, life sciences

核心贡献

领导U.S.大型Pharmaceuticals企业运营

Leading large-scale Pharmaceuticals operations in U.S.

最新观点

  • Johnson & Johnson(2026年Q3业绩公告) · 2026-10-13 阅读原文

    强生董事长兼CEO杜托在2026年10月13日发布三季度业绩时表示,本季度销售额254亿美元、同比增长5.9%,全年有望在公司140年历史上首次突破1000亿美元收入;公司通过OTTAVA(全球首个台面一体化软组织手术机器人)上市、IMAAVY获批以及多发性骨髓瘤三期积极数据等创新推进差异化组合与管线。“这些进展加上在高增长领域的战略投资,让我们更清晰地看到本十年末实现双位数增长的路径。”

    "Johnson & Johnson's strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio. In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade."

  • Nasdaq · 2026-09-16 阅读原文

    9月中旬在摩根士丹利医疗健康大会上表示,公司已更加聚焦于创新药三大领域(肿瘤、免疫、神经科学)和医疗科技三大领域(视力、手术、心血管),目标实现双位数增长

    At the Morgan Stanley Global Healthcare Conference in mid-September, Duato said the company has become more focused around three Innovative Medicine areas (oncology, immunology, neuroscience) and three MedTech areas (vision, surgery, cardiovascular), targeting double-digit growth

  • Johnson & Johnson · 2026-09-14 阅读原文

    表示强生今年上半年营收和盈利均超分析师预期并上调全年指引;尽管Stelara面临生物类似药竞争,但后期管线强劲,相信可治愈特定癌症的疗法正在成为现实

    Said J&J beat analyst expectations for revenue and earnings in the first half of 2026 and raised its full-year outlook. Despite Stelara facing biosimilar competition, the late-stage pipeline is strong and he believes cures for certain cancers are becoming a reality

广告